11:39 AM
 | 
Mar 14, 2018
 |  BC Extra  |  Clinical News

Sarepta resumes dosing at U.K. sites after DMD trial halt

Sarepta Therapeutics Inc. (NASDAQ:SRPT) President and CEO Doug Ingram said the company has resumed dosing at U.K. sites in the Phase III ESSENCE trial evaluating golodirsen (SRP-4053) and casimersen (SRP-4045) to treat Duchenne muscular dystrophy amenable to exon 53 or 45 skipping, respectively. During a presentation Tuesday at the Barclays Global...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >